Malignant News and Research

RSS

Six research institutions awarded NIH grants to create database of human cellular responses

Building on a successful three-year pilot project, the National Institutes of Health has awarded more than $64 million to six research institutions to create a database of human cellular responses, the Library of Integrated Network-based Cellular Signatures.

15 Sep 2014

Merck's Keytruda gets FDA approval for treatment of malignant melanoma

The recent approval of Merck & Co.'s Keytruda by the U.S. Food and Drug Administration for the treatment of malignant melanoma is a significant milestone for Merck & Co. and for the oncology immunotherapy drug market. Decision Resources Group anticipates the launch of Keytruda as the first anti-PD-1 immunotherapy in the United States for treatment of advanced and unresectable malignant melanoma.

10 Sep 2014

RT with concurrent chemotherapy post surgery is effective for treating endometrial cancer

Radiation therapy with concurrent paclitaxel chemotherapy following surgery is an effective treatment for patients with high-risk endometrial cancer, according to a study published in the September 1, 2014 edition of the International Journal of Radiation Oncology ● Biology ● Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO).

10 Sep 2014

Study evaluates impact of myPath Melanoma diagnostic test

Myriad Genetics, Inc. today presented results from a pivotal clinical utility study of the Myriad myPath- Melanoma test at the 2014 College of American Pathologists (CAP) annual meeting in Chicago, Ill.

10 Sep 2014

New breast cancer vaccine provides evidence of immunotherapy in preventing disease recurrence

A new breast cancer vaccine candidate, (GP2), provides further evidence of the potential of immunotherapy in preventing disease recurrence. This is especially the case for high-risk patients when it is combined with a powerful immunotherapy drug.

8 Sep 2014

Soligenix acquires novel orphan drug candidate for treatment of CTCL

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the acquisition of a novel orphan drug candidate, known as SGX301 (synthetic hypericin).

8 Sep 2014

Combination miRNA therapy offers promising therapeutic avenue for non-small-cell lung cancer

Micro RNAs (miRNA) have recently emerged as key therapeutic agents against cancers and are actively being evaluated in pre-clinical models of various cancers as well as in human clinical trials.

8 Sep 2014

Using handheld Raman scanner researchers completely removed brain tumors

Cancerous brain tumors are notorious for growing back despite surgical attempts to remove them - and for leading to a dire prognosis for patients.

4 Sep 2014

Ludwig, CRI collaborate with VentiRx to conduct clinical trial with motolimod and immunotherapy agents

The nonprofits Ludwig Cancer Research (Ludwig) and the Cancer Research Institute (CRI) announced today an agreement with VentiRx Pharmaceuticals Inc., a clinical stage biopharmaceutical company, to conduct a clinical trial with motolimod (VTX-2337) combined with other immunotherapy agents available to Ludwig and CRI through other industry partnerships.

4 Sep 2014

Clinical trial to assess safety and efficacy of novel monoclonal antibody for CLL patients

Researchers at the University of California, San Diego School of Medicine, in partnership with the California Institute for Regenerative Medicine (CIRM) and Celgene Corporation, a New Jersey-based biopharmaceutical company, have launched a phase 1 human clinical trial to assess the safety and efficacy of a novel monoclonal antibody for patients with chronic lymphocytic leukemia (CLL).

4 Sep 2014

One-two punch designed to knock out most dangerous brain cancer

University of Michigan Health System doctors have started testing a unique new approach to fighting brain tumors -- one that delivers a one-two punch designed to knock out the most dangerous brain cancer.

3 Sep 2014

Morbidity, mortality of AF patients remains high at 1 year even with good use of oral anticoagulants

Mortality and morbidity of atrial fibrillation (AF) patients remains high at one year despite good use of oral anticoagulants, according to the one year follow up of the Atrial Fibrillation General Pilot Registry.

1 Sep 2014

Comprehensive fitness and nutrition regimens may prevent bone and muscle deterioration

Being physically active may significantly improve musculoskeletal and overall health, and minimize or delay the effects of aging, according to a review of the latest research on senior athletes (ages 65 and up) appearing in the September issue of the Journal of the American Academy of Orthopaedic Surgeons (JAAOS).

30 Aug 2014

ESMO announces names of outstanding individuals receiving annual awards

The European Society for Medical Oncology, the leading pan-European organisation representing medical oncologists, announced the names of outstanding individuals receiving the Society's esteemed annual awards, to be presented during the ESMO 2014 Congress, on 26 September, in Madrid.

22 Aug 2014

Malignant News and Research

Six research institutions awarded NIH grants to create database of human cellular responses

Merck's Keytruda gets FDA approval for treatment of malignant melanoma

RT with concurrent chemotherapy post surgery is effective for treating endometrial cancer

Study evaluates impact of myPath Melanoma diagnostic test

New breast cancer vaccine provides evidence of immunotherapy in preventing disease recurrence

Soligenix acquires novel orphan drug candidate for treatment of CTCL

Combination miRNA therapy offers promising therapeutic avenue for non-small-cell lung cancer

Using handheld Raman scanner researchers completely removed brain tumors

Ludwig, CRI collaborate with VentiRx to conduct clinical trial with motolimod and immunotherapy agents

Clinical trial to assess safety and efficacy of novel monoclonal antibody for CLL patients

One-two punch designed to knock out most dangerous brain cancer

Morbidity, mortality of AF patients remains high at 1 year even with good use of oral anticoagulants

Comprehensive fitness and nutrition regimens may prevent bone and muscle deterioration

ESMO announces names of outstanding individuals receiving annual awards

CD157 important in malignant pleural mesothelioma

New web-based program helps to determine deadly form of brain cancer

MGH-developed microfluidic device may help study key steps involved in development of tumor metastasis

Researchers use microengineered device to show how EMT cancer cells migrate

Study reports rising prevalence of chronic opioid use by SSDI recipients

Imaging system rapidly detects molecular marker in brain gliomas, enables removal of tumor

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News